Budget credit negative, lacks solutions: Moody's
MUMBAI (Reuters) - India's budget for 2012/13 lacks new solutions to address its fiscal constraints and is credit negative for the sovereign, ratings agency Moody's Investors Service said, after the government set modest targets to rein in a bloated deficit.
"A dependence on corporate tax revenue and vulnerability to commodity prices and exchange rates weakens the government's credit profile," analysts at Moody's said in a statement on Monday.
"And the fiscal 2012/13 budget's lack of specific policies to address these weaknesses is credit negative."
In the absence of new policy initiatives, it will take a combination of improved economic growth, corporate profitability, lower global commodity prices and exchange rate stability to meet the fiscal deficit target in 2012/13, Moody's said.
"Unless subsidy cuts and fuel price increases are introduced in the next few months, expenditure targets will likely be exceeded yet again in fiscal 2012/13," Moody's said, adding that the budget did not elaborate on measures to cap subsidy spending to 1.7 percent of GDP in the next three years.
Moody's currently has a credit rating of BAA3 on the sovereign with a stable outlook.
India's beleaguered government avoided bold reforms in its annual budget on Friday, opting for cautious steps to shore up growth and unveiling only a smattering of anti-deficit measures including an increase in services and excise taxes.
The government set a fiscal deficit target of 5.1 percent of GDP in 2012/13 fiscal year beginning April.
"The budget proposal to expand the number of services that are taxed will yield new revenue sources, but a meaningful effect on overall revenue ratios will take several years since service taxes contribute only 5 percent of current tax revenues," Moody's said.
(Editing by Aradhana Aravindan)
- Tweet this
- Share this
- Digg this
Indian drugmakers are fleeing a regulatory morass at home and moving some research and development to Europe and the United States as try to boost margins by producing high-value drugs. India's $15 billion a year pharma industry is already reeling from a string of drug recalls and quality control issues which have called into question the regulator's oversight. Full Article
Adani buys Australia coal mine royalty rights from Linc for $145 million Full Article